Samsung Medical Center
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
Retinal Layers and Visual Rehabilitation After Epiretinal Membrane Removal
Not Applicable
Completed
- Conditions
- Epiretinal Membrane
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2011-11-18
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 52
- Registration Number
- NCT01474655
Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma
Phase 2
Completed
- Conditions
- Advanced or Recurrent Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: Capecitabine/Cisplatin(XP)Drug: Capecitabine/Paditaxel(XG)
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 64
- Registration Number
- NCT01474642
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Elongation of Foveal Tissue After Macular Hole Surgery
Not Applicable
Completed
- Conditions
- Macular Holes
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 31
- Registration Number
- NCT01471912
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma
Completed
- Conditions
- Metastatic Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 239
- Registration Number
- NCT01472419
A Prospective Study of Pharmacogenetic Factors and Gene Expression Profile
- Conditions
- Colon Cancer
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 2660
- Registration Number
- NCT01472601
- Locations
- π°π·
Samsung medical Center, Seoul, Korea, Republic of
Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma
Phase 3
- Conditions
- Biliary Tract (Intrahepatic, Extrahepatic Cholangiocarcinoma, Gall Bladder) Cancer
- Interventions
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 240
- Registration Number
- NCT01470443
- Locations
- π°π·
Samsung medical Center, Seoul, Korea, Republic of
Pharmacogenomic Study (Adjuvant Chemotherapy)
Completed
- Conditions
- Gastric Cancer
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 792
- Registration Number
- NCT01470404
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Samsung Medical Center
- Registration Number
- NCT01470742
- Locations
- π°π·
Samsung medical Center, Seoul, Korea, Republic of
Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer
Phase 2
Completed
- Conditions
- Metastatic CarcinomaRecurrent Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: Gemcitabine/Docetaxel
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT01469598
- Locations
- π°π·
Samsung medical Center, Seoul, Korea, Republic of
A Trial of JX-594 in Refractory Colorectal Carcinoma
Phase 1
Completed
- Conditions
- Colorectal Carcinoma
- Interventions
- Biological: JX-594
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT01469611
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath